Emotional self‐regulation and impulse control (no study reported data on this outcome) · young people (aged 10 to 18 years old) with harmful sexual behaviour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recidivism: behavioural reports of sexual aggression Measured by: Daily Behaviour Report cards and Behaviour Incidence Report forms completed by staff · young people (aged 10 to 18 years old) with harmful sexual behaviour
1 finding from 1 review
Adverse events None of the included studies evaluated adverse events · young people (aged 10 to 18 years old) with harmful sexual behaviour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · people with dementia
1 finding from 1 review
Social functioning measured using MOSES, Withdrawn Behaviour subscale (8‐ 32, higher score indicates more severe withdrawn behaviour) · people with dementia
1 finding from 1 review
Behaviour · people with dementia
1 finding from 1 review
Agitation and irritability · people with dementia
1 finding from 1 review
Health‐related quality of life measured using QUALID (12–45, higher score indicates poorer quality of life) · people with dementia
1 finding from 1 review
Adverse events · people with dementia
The review found no eligible studies for this question.
1 finding from 1 review
ADL outcome · people with dementia
1 finding from 1 review
Physical functioning: self‐care ability measured using MOSES Self‐Care Functioning subscale (8–32, higher score indicates poorer function) · people with dementia
1 finding from 1 review
Overall survival (OS) · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, · stage III cutaneous melanoma
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).
1 finding from 1 review
Overall response rate (ORR), · stage III cutaneous melanoma
1 finding from 1 review
Time to recurrence ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death Number of deaths over 36 months · stage III and IV cutaneous melanoma
1 finding from 1 review
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
Overall response rate (ORR), · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
Time to recurrence · stage III and IV cutaneous melanoma
1 finding from 1 review